The 2025 International Summit on Human Genome Editing called for: • A moratorium on heritable edits until safety and societal consensus are achieved Meanwhile, patients with devastating genetic ...

CRISPR technology, targeting genetic diseases and cancer, may bring major biotech stock growth. CRISPR Therapeutics and Intellia show progress with clinical trials and big pharma partnerships.

Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins are core components of fast-evolving therapeutic gene editing tools. Scientists have used CRISPR ...

In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...

In gene and cell therapy, RNP-mediated CRISPR gene editing is quickly emerging as the new norm. For many gene editing firms, GenScript has created hundreds of Cas9, Cas12a, Cas13a, MAD7, ABE, CBE, and ...